Liquid Biopsy–Based Profiling of TP53 Gene Hotspot Mutations in HBV‐Induced Chronic Liver Disease and Hepatocellular Carcinoma Patients: A Study From Bangladesh
International Journal of Hepatology · 2026-01 · 2026 (1)
DOI: 10.1155/ijh/6175143 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Hepatology, online erschienen am 17.08.2026. Verfasst von Sabinur Akter und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Virology, Bangladesh Medical University (BMU), Dhaka, Bangladesh. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The tumor protein ( TP53 ) gene is a common driver gene for somatic mutations in hepatocellular carcinoma(HCC), and detection may provide insight into evaluating disease progression. Circulating cell‐free DNA (cfDNA) from liquid biopsy has emerged as a promising noninvasive biopsy material for identifying potential genetic alterations. This study explored the mutational signature of the TP53 gene in Hepatitis B virus (HBV)–infected chronic liver disease (CLD) and HCC patients from cfDNA.
Method
A total of 80 participants: 30 HCC, 30 CLD, and 20 healthy controls were included in this cross‐sectional study. cfDNA was extracted from aseptically collected peripheral venous blood. TP53 (R249S) gene was amplified using selected primers via conventional PCR and visualized on a 2% agarose gel electrophoresis. Amplified products underwent Sanger sequencing; mutational analysis was done using MEGA11 software compared with the reference sequence.
Result
TP53 hotspot mutations were found in 23.3% (7/30) of HCC patients. Mutational frequencies were detected: 13.3% (4/30) at position 746G > A (R249S), 6.7% (2/30) at 747G > A (R249S), and 3.3% (1/30) at 735C > T (G245S). Among CLD patients, a single hotspot mutation (3.3%) was detected at position 744G > A/T(R248Q/W). However, no hotspot mutation was detected in healthy controls. All HCC patients with mutations (7/7, 100%) had elevated ALT, AST, serum bilirubin, and AFP levels, and in the unmutated (wild) group, these were 69.6%, 47.8%, 30.4%, and 60.9%, respectively. The mean AST and AFP levels were significantly higher in mutated patients compared with the wild group.
Conclusion
Detection of TP53 gene mutations along with biochemical markers in the management of HCC is evident, and it may play an important role in targeted therapy and personalized treatment plans.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Virology, Bangladesh Medical University (BMU), Dhaka, Bangladesh.
- Department of Microbiology, Shaheed Mansur Ali Medical College & Hospital, Dhaka, Bangladesh.
- Programme of Emerging Infections (PEI), Infectious Disease Division (IDD), icddr, b, Dhaka, Bangladesh, icddrb.org.
ORCID-Profile: Sabinur Akter, Sharmin Sultana, Md Zulqarnine Ibne Noman, Farzana Laila, Afzalun Nessa
Zitieren
APA
Akter, S., Sultana, S., Noman, M. Z. I., Laila, F., & Nessa, A. (2026). Liquid Biopsy–Based Profiling of TP53 Gene Hotspot Mutations in HBV‐Induced Chronic Liver Disease and Hepatocellular Carcinoma Patients: A Study From Bangladesh. International Journal of Hepatology, 2026(1). https://doi.org/10.1155/ijh/6175143
Vancouver
Akter S, Sultana S, Noman MZI, Laila F, Nessa A. Liquid Biopsy–Based Profiling of TP53 Gene Hotspot Mutations in HBV‐Induced Chronic Liver Disease and Hepatocellular Carcinoma Patients: A Study From Bangladesh. International Journal of Hepatology. 2026;2026(1). doi:10.1155/ijh/6175143
BibTeX
@article{Akter2026,
author = {Akter, Sabinur and Sultana, Sharmin and Noman, Md Zulqarnine Ibne and Laila, Farzana and Nessa, Afzalun},
title = {Liquid Biopsy–Based Profiling of TP53 Gene Hotspot Mutations in HBV‐Induced Chronic Liver Disease and Hepatocellular Carcinoma Patients: A Study From Bangladesh},
journal = {International Journal of Hepatology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/ijh/6175143}
}
EUVIMED